Metabasis Therapeutics, Inc. (NASDAQ: MBRX), a biopharmaceutical company, focuses their efforts on discovering, developing and commercializing innovative drugs by applying its scientific expertise, proprietary technologies and unique capabilities for targeting the liver and liver pathways. The company has established advanced research programs and a broad pipeline of product candidates, all of which were developed through the leveraging of their proprietary technologies. For further information, visit the Company’s web site at www.mbasis.com.
- 18 years ago
QualityStocks
Metabasis Therapeutics, Inc. (NASDAQ: MBRX)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Closer to Regulatory and Commercial Milestones
Regentis Biomaterials (NYSE American: RGNT) is advancing its GelrinC hydrogel-based cartilage regeneration technology toward key clinical, regulatory…
-
Wrap Technologies Inc. (NASDAQ: WRAP) Positions Non-Lethal Innovation at the Center of Public Safety Reform
WRAP offerings illustrate a broader industry trend toward building connected ecosystems rather than standalone products.…
-
Brownfield Gold Projects Could Hold an Edge in Today’s Permitting Environment
Disseminated on behalf of Lahontan Gold Corp. (TSX.V: LG) (OTCQB: LGCXF) and may include paid advertising.…